著者

Miki Nonaka Nagomi Kurebayashi Takashi Murayama Masami Sugihara Kiyoshi Terawaki Seiji Shiraishi Kanako Miyano Hiroshi Hosoda Shosei Kishida Kenji Kangawa Takashi Sakurai Yasuhito Uezono

出版者

The Japan Endocrine Society

雑誌

Endocrine Journal (ISSN:09188959)

巻号頁・発行日

vol.64, no.Suppl., pp.S35-S39, 2017 (Released:2017-06-24)

参考文献数

14

被引用文献数

2 9

---

Cancer was considered an incurable disease for many years; however, with the development of anticancer drugs and state-of-the art technologies, it has become curable. Cardiovascular diseases in patients with cancer or induced by cancer chemotherapy have recently become a great concern. Certain anticancer drugs and molecular targeted therapies cause cardiotoxicity, which limit the widespread implementation of cancer treatment and decrease the quality of life in cancer patients significantly. The anthracycline doxorubicin (DOX) causes cardiotoxicity. The cellular mechanism underlying DOX-induced cardiotoxicity include free-radical damage to cardiac myocytes, leading to mitochondrial injury and subsequent death of myocytes. Recently, circulating orexigenic hormones, ghrelin and des-acyl ghrelin, have been reported to inhibit DOX-induced cardiotoxicity. However, little is known about the molecular mechanisms underlying their preventive effects. In the present study, we show the possible mechanisms underlying the effects of ghrelin and des-acyl ghrelin against DOX-induced cardiotoxicity through in vitro and in vivo researches.

著者

Tetsuo TAKENAKA Takashi MURAYAMA Tadasu FURUSHO Yoko TAKENAKA

出版者

Japanese Society for Food Science and Technology

雑誌

Food Science and Technology Research (ISSN:13446606)

巻号頁・発行日

vol.15, no.5, pp.541-546, 2009 (Released:2009-12-22)

参考文献数

16

被引用文献数

4 5

---

The effect of the ACE inhibitor nicotianamine (NA), from soybean broth (SB), on blood pressure was investigated in spontaneously hypertensive rats (SHR) upon single and long-term administration. The IC50 value of NA from SB was 0.69 μmol/L. Single oral dose of NA (0.9 mg, 4.5 mg and 9.0 mg/kg body weight) decreased blood pressure 1 h after administration, and blood pressure returned to the control level 3 h after administration. Long-term oral dose of NA (0.9 mg and 4.5 mg/kg body weight) decreased blood pressure for 4 weeks after administration, while that of NA (9.0 mg/kg body weight) was decreased for the full 8-weeks feeding period. At 8 weeks after administration, serum NA content in SHR was determined by amino acid analyzer and revealed that NA was not detected in the blood of SHR (0.9 mg and 4.5 mg/kg body weight group), while 32.6 ± 7.3 μg/dL NA was detected in the 9.0 mg/kg body weight group. It was suggested that NA absorbed from the intestine decreased the systolic blood pressure (SBP) in SHR, and an appropriate NA level (9.0 mg/kg body weight group) may provide long-term antihypertensive effects upon administration.